Imm2510, imm27m
Phase 2
Imm2510, imm27m is one of 4 therapeutic programs targeting HCC - Hepatocellular Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in HCC - Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1QL1706
Qilu Pharmaceutical Co., Ltd.Approved
Immunotherapy
Bristol-Myers SquibbPhase 2
Targeted Therapy
FFudan University
Phase 2
Imm2510, imm27m
IImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Imm2510, imm27m. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]